Editor’s Note: The biggest IPO winners are NOT in AI, robotics or space. An overlook group of IPOs have seen crazy gains in the last couple years. This includes 756% for IonQ, 1,332% for BTQ and 2,637% for D-Wave. |
Don’t worry if you missed these winners. Because a new Pre-IPO could be the next big winner. And there’s still time for you to invest. |
Simply go here for step-by-step instructions. |
Two of the biggest names in pharma are backing a CRISPR company going public this week. |
Scribe Therapeutics (Nasdaq: SCTX)
Price Range: $13–$15
Deal Size: ~$100 million
Market Cap at IPO: ~$243 million
Expected Pricing: Thursday, July 23
Expected Trading: Friday, July 24 |
Scribe is a clinical-stage biotech engineering CRISPR-based gene-silencing therapies. Its lead program targets high cholesterol. |
Eli Lilly (NYSE: LLY) plans to invest $10 million in the deal — around 10% of the offering. Sanofi (Nasdaq: SNY) is buying another $7.5 million through a concurrent private placement. |
When large drugmakers put money into an IPO, it's a meaningful signal. We saw the same pattern with Aktis Oncology and Veradermics, where Lilly's involvement preceded strong runs. |
Aktis is up 37% and Veradermics is up 544% since going public. |
Scribe is worth a closer look for another reason. It's one of the first gene-editing companies to attempt an IPO in years. The last one to price was Metagenomi back in 2024. The category has been mostly frozen since biotech peaked in 2021. |
The science is ambitious. Scribe uses epigenetic silencing to switch off genes without permanently cutting DNA. Its lead drug, STX-1150, targets PCSK9 — the same protein behind injectables like Repatha. The pitch is a single dose that lowers LDL cholesterol durably, instead of daily pills or quarterly shots. |
The company was co-founded in 2017 by Benjamin Oakes, a former researcher in the lab of Nobel laureate Jennifer Doudna, who co-discovered CRISPR-Cas9 and serves as a scientific advisor. Backers include Andreessen Horowitz, Avoro, and OrbiMed. |
This is early-stage biotech in the truest sense. STX-1150 just entered its first human trial in Australia, and initial data isn't expected until the first half of 2027. There are no approved products and no recurring revenue. A weak readout could cut the stock sharply. |
Health care IPOs have returned an average of 43% in 2026, and recent biotech debuts like Kardigan and Parabilis both jumped after listing. The IPO window is for these types of biotech companies is now open. |
Scribe is set to price Thursday and trade Friday. |
Do you want to invest in the next big IPO – right before it starts trading? |
Get all the details on my #1 new Pre-IPO for 2026. |
Here’s a link to get the details. |
Ian Wyatt
Editor, IPO Watch |
|
0 التعليقات:
إرسال تعليق